Icecure MedicalICCM -15.10%46 EBITDA Margin % is -458.62% as of Mar. 2026. GuruFocus rates ICCM with a GF Score™ of 46/100 and a GF Value™ of $21.37 (Possible Value Trap). The stock has 4 warning signs investors should review. Among 817 Medical Devices & Instruments companies, Icecure Medical ranks worse than 91.43% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. Icecure Medical's EBITDA for the
three
months ended in Mar. 2026 was $-4.18 Mil. Icecure Medical's Revenue for the
three
months ended in Mar. 2026 was $0.91 Mil. Therefore, Icecure Medical's EBITDA margin for the quarter that ended in Mar. 2026 was -458.62%.
Icecure Medical (NAS:ICCM) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Icecure Medical EBITDA Margin % Related Terms
Icecure Medical EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Icecure Medical's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ICCM vs IRIX, ADGM, CSDX: EBITDA Margin % Comparison
For the Medical Devices subindustry, Icecure Medical's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Icecure Medical EBITDA Margin % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Icecure Medical's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Icecure Medical's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Icecure Medical (ICCM) has a EBITDA Margin % of -458.62% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Icecure Medical and its competitors. According to the industry distribution chart, Icecure Medical ranks #747 out of 817 companies in the Medical Devices & Instruments industry, placing it in the top 91.4%.
Is Icecure Medical's EBITDA Margin % too high?
Icecure Medical's current EBITDA Margin % is -458.62%. Based on the distribution chart, Icecure Medical ranks #747 out of 817 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Icecure Medical has a GF Score™ of 46/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Icecure Medical's EBITDA Margin % compare to IRIX and ADGM?
According to the Medical Devices & Instruments industry distribution chart, Icecure Medical ranks #747 out of 817 companies for EBITDA Margin %. This places Icecure Medical in the lower half of its industry. The industry median EBITDA Margin % is 7.44. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Medical Devices & Instruments company?
The median EBITDA Margin % among Medical Devices & Instruments companies is 7.44, based on 817 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Icecure Medical and its competitors. For the Medical Devices & Instruments industry, the median EBITDA Margin % is 7.44 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Icecure Medical's current EBITDA Margin % is -458.62%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Icecure Medical stock overvalued right now?
Based on GuruFocus' analysis, Icecure Medical (ICCM) is currently considered Possible Value Trap. The stock's GF Value™ is $21.37, compared to a current price of $5.92 — trading 72.3% below its estimated fair value. The current EBITDA Margin % is -458.62%. Icecure Medical's overall GF Score™ is 46/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Icecure Medical (ICCM), the current EBITDA Margin % is -458.62% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Icecure Medical (ICCM) Overvalued in 2026?
Based on GuruFocus' analysis, Icecure Medical stock appears to be undervalued.
The current stock price of $5.92 is trading 72.3% below its estimated GF Value™ of $21.37.
GuruFocus considers Icecure Medical to be Possible Value Trap.
Key valuation signals for ICCM:
EBITDA Margin %: -458.62%
GF Value™: $21.37 vs. price of $5.92 (72.3% below fair value)
No single metric tells the full story. See the ICCM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Icecure Medical Ltd is a commercial-stage medical device company. The company is engaged in the research, development, and marketing of cryoablation systems and technologies based on liquid nitrogen, or LN2, for treating tumors. Its cryoablation technology is a minimally invasive alternative to surgical intervention for tumors, including those found in the breast, lungs, kidneys, bones, and other indications.
46GF Score
Get the complete analysis for ICCM
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ICCM has been successfully added to your 
